Active clinical trials

If you are interested in participating in a clinical trial, please visit NLStudies Connect to learn more. Below are some areas where active clinical trials are in place.

• Randomized comparison of the clinical outcome of single versus multiple arterial grafts in women
• Aggressive smoking cessation therapy post-acute coronary syndromeGenePHIT
• The direct oral anticoagulation versus vitamin K antagonist after cardiac surgery
• Beta blocker deprescription following coronary artery bypass graft surgery: feasibility and safety pilot
• A focused sub-study of the International Kawasaki Disease Registry (IKDR)
• Cardiac sarcoidosis multi-centre randomized controlled trial
• CRD-973 SyncAV post-market trial
• A randomized trial of physiology-guided versus angiography-guided non-culprit lesion (NCL) complete revascularization strategies and a large-scale observational study of optical coherence tomography in patients with acute myocardial infarction and multivessel coronary artery disease
• Targeted therapy with glycogen synthase kinase-3 inhibition for arrhythmogenic cardiomyopathy (TARGET)
• COMMENCE Trial – A randomized controlled trial of mild versus moderate hypothermia on patient outcomes in aortic hemiarch surgery with anterograde cerebral perfusion
• Treatment in thoracic aortic aneurysm: surgery versus surveillance (TITAN: SvS)

• Health research innovation team in multiple sclerosis (HIT MS) provincial portfolio

• Canadian Fabry Disease Initiative National Registry: outcome of rare disease therapeutics and cardiovascular risk factor modification.

• Canadian adaptive platform trial of treatments for COVID-19 in community settings
• Assessing the implementation of point-of-care multiplex-viral testing in primary care
• A randomized, double-blind, placebo-controlled Phase III study of VE303 for prevention of recurrent Clostridioides Difficile infection: the restorative 303 study
• Recovering from COVID-19 lingering symptoms adaptive integrative medicine
• Characterization of cellular and humoral immunity against SARS-CoV-2
• Assessing immunogenicity of COVID-19 vaccines in survivors of hematological and solid Cancers
• Immunogenicity and durability of COVID-19 vaccines in persons living with human immunodeficiency virus
• National program of hospital surveillance system for vaccine-related event

• Pediatric outcomes improvement through coordination of research networks (POPCORN): COVID-19 Platform Prospective Cohort Study

• Tailor RT: A randomized trial of regional radiotherapy in biomarker low risk node positive and T3N0 breast cancer
• A phase III, multicentre, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Inavolisib in combination with Phesgo® versus placebo in combination with Phesgo® as maintenance therapy after first line induction therapy in participants with PIK3CA‑mutated HER2‑positive locally advanced or metastatic breast cancer
• MRI brain surveillance alone versus MRI surveillance and prophylactic cranial irradiation (PCI): a randomized phase III trial in small-cell lung cancer (MAVERICK)
• Precision oncology for young people project
• The NEO-RT trial. A phase III randomized trial of neoadjuvant chemotherapy, excision and observation versus chemoradiotherapy for early rectal cancer
• Androgen suppression combined with elective nodal irradiation and dose escalated prostate treatment: a non-inferiority, phase III randomized controlled trial of stereotactic body radiation therapy versus brachytherapy boost in patients with unfavourable risk localized prostate cancer (ASCENDE-SBRT)
• NRG-GI008: colon adjuvant chemotherapy based on evaluation of residual disease
• A phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2- expressing recurrent endometrial cancer
• An open-label, randomized phase III trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum Doublet Chemotherapy versus Platinum Doublet Chemotherapy in subjects with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer
• Datopotamab Deruxtecan (Dato-DXd) in combination with Rilvegostomig (AZD2936) or Rilvegostomig monotherapy versus Pembrolizumab monotherapy for the first-line treatment of participants with locally-advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations (TROPION-Lung10)
• MY:13 a phase III non-inferiority randomized controlled trial of fixed duration versus continuous daratumumab among transplant ineligible older adults with newly-diagnosed multiple myeloma
• Multicentre pilot trial (MYELO-CAN): Evaluation of supportive care treatments among outpatients with myelodysplastic syndrome and acute myeloid leukemia
• BOREALIS Trial: A single arm, response-adapted, open label study of Iberdomide, weekly bortezomib and dexamethasone (IberBd) with isatuximab added on demand for transplant-ineligible, newly diagnosed multiple myeloma patients
• A Phase III open label multicentre study comparing BGB-16673 versus investigator choice of Rituximab plus either Lenalidomide or Bendamustine in patients with relapsed/refractory mantle cell lymphoma
• A multi-phase, dose-escalation followed by an open-label, randomized, crossover study of oral ASTX030 (Cedazuridine and Azacitidine given in combination) versus subcutaneous Azacitidine in subjects with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML)
• A Phase III randomized, open-label, multicentre study of Zanubrutinib (BGB-3111) plus anti-CD20 antibodies versus Lenalidomide plus Rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma
• A randomized Phase II study of Pembrolizumab and Brentuximab Vedotin versus GDP, followed by high dose chemotherapy and autologous stem cell transplantation for relapsed/refractory classical Hodgkin Lymphoma (HD.11)
• The PATH Phase III Trial: Platelet transfusions in hematopoietic stem cell transplantation
• Retrospective chart review of patients with paroxysmal nocturnal hemoglobinuria (PNH) in Canada
• A randomized, controlled Phase III study of Pacritinib versus physician’s choice in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis with severe thrombocytopenia (platelet counts < 50,000/µL)
• A Phase III, two-stage, randomized, multicentre, open-label study comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in subjects with relapsed or refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)
• A randomized, double-blind, placebo-controlled, active-comparator, multicentre, Phase III study of Brentuximab Vedotin or placebo in combination with Lenalidomide and Rituximab in subjects with relapsed or refractory diffuse large B-cell Lymphoma (DLBCL)
• Canadian Acute Leukemia Registry
• Post-authorization safety study to evaluate the incidence of and risk factors for severe and fatal infusion-related reactions in participants treated with Daratumumab (intravenous or subcutaneous)
• Capturing Canadian real-world data for AML chemotherapy-ineligible patients on Venetoclax
• Myeloma Canada Research Network Database
• Hematology Oncology Database of Newfoundland and Labrador
• A multi-country, prospective observational study of Epcoritamab in NHL comprising two patient cohorts (3L+(D)LBCL and 3L+FL)
• CFDNA in hereditary and high-risk malignancies (CHARM) 2: Evaluating the performance of a cfDNA blood test for early cancer detection
• A multi-centre Phase II/III randomized controlled study circulating tumour DNA analysis informing adjuvant chemotherapy in Stage III colon cancer (DYNAMIC-III)
• A Phase III trial of a short-term androgen deprivation with pelvic node or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with rising PSA after radical prostatectomy
• Androgen deprivation therapy and high dose radiotherapy with or without whole pelvic radiotherapy in unfavourable intermediate or favourable high risk prostate cancer: a Phase III randomized trial
• A Phase III study of hypofractionated dose escalation radiotherapy versus conventional pelvic radiation therapy followed by high dose rate brachytherapy boost for high-risk adenocarcinoma of the prostate
• A randomized Phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically-localized prostate cancer.
• A Phase III prospective double-blind placebo-controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer (BR.31)
• A randomized, parallel group, non-inferiority trial comparing random and targeted biopsies to targeted biopsies alone for neoplasia detection during screening colonoscopy in adults with colonic inflammatory bowel diseases: a pilot study (IBD-Dysplasia)
• PLAN Trial – Prevention of persistent pain with Lidocaine infusions in breast cancer surgery

• A randomized clinical trial evaluating fixation insitu versus removal for midfoot lisfranc injurie
• A randomized controlled study of a local osteo-enhancement procedure (LOEP) to prevent secondary hip fractures in osteoporotic women undergoing treatment of index hip fractures
• A randomized controlled trial comparing antibiotic cement bead pouch versus negative pressure wound therapy for the management of severe open tibia fracture wounds
• A two-part prospective, randomized, multi-centre, clinical trial on the retrograde nailing versus open reduction and internal fixation for unstable fractures around the ankle in the frail elderly

• Antithrombotic therapy to ameliorate clinical complications in community acquired pneumonia
• Randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia
• Pilot for a test-negative case-control study to evaluate the effectiveness of a new adult pneumococcal vaccine against Pneumococcal Pneumonia in older adults

• A study of the efficacy and safety of Bimekizumab in participants with active psoriatic arthritis in comparison to Risankizumab
• A Phase III, multi-centre, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of JNJ-77242113 for the treatment of biologic-experienced participants with active psoriatic arthritis
• A multi-centre, prospective study to evaluate the impact of modifying the validated
• Psoriasis Epidemiology Screening Tool (PEST) on the potential diagnosis of psoriatic arthritis in adult patients with moderate-to-severe plaque psoriasis in Canada
• A Phase IV, multi centre, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Guselkumab administered subcutaneously in bio-naive participants with active psoriatic arthritis axial disease
• A Phase III, randomized, double blind study comparing ABT 494 to placebo and to Adalimumab in subjects with moderately to severely active rheumatoid arthritis who are on a stable background of Methotrexate (MTX) and who have an inadequate response to MTX (MTX-IR)
• Assessment of Guselkumab (Tremfya) and IL-17 inhibitor therapies in patients with psoriatic arthritis in routine clinical practice: a prospective, observational cohort study
  Preventing arthritis in a multi-centre psoriasis at-risk cohort (multi-centre PAMPA study)

• A platform trial for gram negative bloodstream infection
• Piperacillin Tazobactam versus Meropenem for treatment of bloodstream infections caused by cephalosporin-resistant enterobacteriaceae – a non-inferiority randomized controlled trial
• Pandemic preparedness engaging primary care and emergency departments (PREPARED)
• Staphylococcus aureus network adaptive platform trial
• Cognitive behavioural therapy to optimize post-operative recovery (COPE): A randomized controlled trial
• Using antibiotics wisely – an antimicrobial stewardship program
• Canadian Neonatal Network
• Canadian Neonatal Transport Network
• Evidence-based practice for improving quality
• Canadian Preterm Birth Network
• Canadian Pediatric Surgery Network
• Withholding enteral feeds around the time of transfusion
• Does the use of higher versus lower oxygen concentration improve neurodevelopmental outcomes at 18 to 24 months in very low birthweight infants?
• Post-extubation pressures on non-invasive respiratory support in preterm neonates: a prospective comparative effectiveness research study
• Rick Hansen spinal cord injury